Article

Oral Blarcamesine Phase IIb/III Trial Confirms Identified Precision Medicine Patient Population – Significant Broad Clinical and Quality of Life Improvements for Early Alzheimer’s Disease Patients

2025-09-29

Abstract excerpt

<h4>IMPORTANCE</h4> There are no approved oral disease-modifying treatments for Alzheimer’s disease (AD) with the ability to prolong time in a stable disease state and with clinically meaningful outcomes clear to patients and caregivers. <h4>DESIGN</h4> The Phase IIb/III ANAVEX2-73-AD-004 study was a randomized, double-blind, placebo-controlled, 48-week trial with prespecified gene or GWAS identified genetic var...

Topics

Open a Topic to create a Post that cites this publication.

Identifiers and source

Literature Corpus work: 59d20c87-b8a4-5e19-8d4e-00c0dff9b864
DOI: 10.1101/2025.09.27.25336656

Open publication

Related research

Semantic proximity does not establish scientific evidence.

Click a neighbor to travelStep 1 · 12 closest

Oral Blarcamesine Phase IIb/III Trial Confirms Identified Precision Medicine Patient Population – Significant Broad Clinical and Quality of Life Improvements for Early Alzheimer’s Disease PatientsDOI 10.1101/2025.09.27.25336656Read

Precision Medicine Treatment of Alzheimer’s Disease: Successful Randomized Controlled TrialSemantic proximity Read

Repurposing bromocriptine for Aβ metabolism in Alzheimer's disease (REBRAnD) study: randomised placebo-controlled double-blind comparative trial and open-label extension trial to investigate the safety and efficacy of bromocriptine in Alzheimer's disease with presenilin 1 (PSEN1) mutations.Semantic proximity Read

Novel Therapeutic Strategies for DementiaSemantic proximity Read

The Alzheimer’s disease drug development landscapeSemantic proximity Read

Biologics as Therapeutical Agents Under Perspective Clinical Studies for Alzheimer’s DiseaseSemantic proximity Read

Therapeutic Options in Alzheimer’s Disease: From Classic Acetylcholinesterase Inhibitors to Multi-Target Drugs with Pleiotropic ActivitySemantic proximity Read

An interim exploratory biomarker analysis of a Phase 2 clinical trial to assess the impact of CT1812 in Alzheimer’s diseaseSemantic proximity Read

Precision Medicine Approach to Alzheimer’s Disease: Successful Proof-of-Concept TrialSemantic proximity Read

Baseline demographic, clinical, and cognitive characteristics of the Alzheimer's Prevention Initiative (API) Autosomal-Dominant Alzheimer's Disease Colombia Trial.Semantic proximity Read

Combining genetics with real-world patient data enables ancestry-specific target identification and drug discovery in Alzheimer’s diseaseSemantic proximity Read

Stratified cohorts for biomarker assessment and trial readiness: <i>TMEM175</i> , <i>SCARB2</i> and <i>CTSB</i> in Parkinson’s diseaseSemantic proximity Read